Mawson Infrastructure Group (OTCMKTS:WIZP) & AEON Biopharma (NASDAQ:AEON) Head-To-Head Contrast

AEON Biopharma (NASDAQ:AEON) and Mawson Infrastructure Group (OTCMKTS:WIZP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Profitability

This table compares AEON Biopharma and Mawson Infrastructure Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Mawson Infrastructure Group	N/A	N/A	-85.32%

Analyst Ratings

This is a summary of recent ratings for AEON Biopharma and Mawson Infrastructure Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
Mawson Infrastructure Group	0	0	0	0	0.00

AEON Biopharma currently has a consensus price target of $360.00, indicating a potential upside of 48,352.22%. Given AEON Biopharma’s stronger consensus rating and higher possible upside, research analysts plainly believe AEON Biopharma is more favorable than Mawson Infrastructure Group.

Volatility & Risk

AEON Biopharma has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Mawson Infrastructure Group has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Institutional & Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares AEON Biopharma and Mawson Infrastructure Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	($6.08)	-0.12
Mawson Infrastructure Group	N/A	N/A	-$3.45 million	($0.33)	-1.23

Mawson Infrastructure Group is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

AEON Biopharma beats Mawson Infrastructure Group on 6 of the 10 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Mawson Infrastructure Group

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia.